"Soframycin" is readily absorbed when given parenterally, but because of toxicity it is not given therapeutically by this route. By contrast "soframycin" is but poorly absorbed when given orally because the intestinal barrier is almost impermeable to it and thus the antibiotic can exert a sustained effect on the intestinal flora.
It is necessary to reach a single oral dose of 4 g. of "soframycin" before blood concentrations become measurable (about 1 ,tg. per ml.) (Massdnat-Deroche, loc. cit.). In therapeutic doses absorption is so poor that there are no systemic effects, as estimations of blood "soframycin" levels have repeatedly shown.
The urinary levels are too low to cause any renal damage (Marquezy, Debray, Leveau, Grenier, and Lepage, 1955) .
CLINICAL TRIALS
The clinical trial was conducted on 22 patients in the wards of Whittington or Hornsey Central Hospitals. All the patients to whom the drug was given were cases in which the bowel had to be divided for resection of a growth, for the establishment of a colostomy or ileostomy, or for the utilization of a portion of the bowel for another purpose, e.g., ileal loop bladder or ureteroplasty. In all cases the patients were in hospital when the "soframycin" was administered. The drug was given in tablet form by mouth, 0.5 g. eight-hourly in the majority of cases, the total dosage varying from 2 g. to 4 g. The time and dose were recorded.
Patients were prepared for operation by the routine method used in the unit. No aperients were given but they had bowel washouts on the morning of the operation, on the evening preceding operation, and on the evening preceding that, i.e., three in all. In the cases marked with a star in the Table, 250 mg. of "soframycin" in 60 ml. saline was instilled into the bowel after each washout and left to be passed by the patient as desired.
BACTERIOLOGICAL RESULTS
As far as possible, examination was made of (1) a specimen of stool passed recently before the first dose of "soframycin"; (2) a specimen passed after the last dose of "soframycin" and before operation; and (3) specimens of intestinal contents taken from the lumen of the portion of intestine removed at operation.
The specimens were examined on a quantitative basis, except in the case of small amounts of mucus or tissue, from the area of a malignant growth. The method was as follows:-Weigh two equal portions of stool, approximately 1 g. Emulsify one portion in 100 ml. saline and dilute this emulsion 1 in 10, 1 in 100, and 1 in 1,000 in saline. Culture 0.1 ml. of each of these dilutions on desoxycholate citrate agar medium, on blood agar medium incubated aerobically, and on blood agar incubated anaerobically. After incubation, count the colonies on In all cases the drug caused a marked reduction in the intestinal bacterial content, particularly in the coliform group of organisms and of Cl. welchii. Comparatively, enterococci were more resistant but they were much reduced in almost all patients. In several instances (Cases 15, 16, and 17) there was no growth of organisms at all in the stool after total dosages of 2 or 3 g. "Soframycin" was not detected by the disc technique in the specimens tested.
In only one case in which "soframycin" was used was there subsequent sepsis or complication of any kind, namely, in Case 8, a patient who had vesicovaginal and vaginocolic fistulae after previous radiotherapy for advanced carcinoma of the cervix, with gross sepsis before operation. One patient died from a pulmonary embolus on the sixth day after operation, and one, uraemic before operation, died in uraemia on the tenth post-operative day.
SIDE-EFFECTS
There were no side-effects attributable to the drug in any of the cases treated. In addition to the abovementioned patients a number of others were prepared for resection of bowel but no resection was done at operation nor did they show any evidence of side-effects from the administration of the drug. SUMMARY "Soframycin" was given in total dosage of 2 to 4 g. to 22 patients before operations involving division of the large intestine (18 cases) or small intestine (four cases). The drug led to a very great reduction or to the complete absence of viable bacteria in the stools or at the site of surgical operation. Postoperative infection of the peritoneum or intestinal or surface wounds was absent in all patients except one whose tissues were severely infected before operation. Undesirable side-effects from the drug were not found.
